Skip to main content
    G

    Gyre Therapeutics Inc. (GYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.55
    -1.86 (-28.94%)

    Market Cap: $482.98M

    Last updated: Oct 30, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    22%(8/36)
    Avg Surprise
    -1291.56%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.19 - $-0.06
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07-59.2%
    60d ago$-0.07-59.2%
    30d ago$-0.07-59.2%
    7d ago$-0.07-59.2%
    Current$-0.12
    Revenue Consensus
    $28M
    Range$28M - $29M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.36 - $0.03
    3 analysts
    Revenue Consensus
    $23M
    Range$22M - $24M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.12---
    Jun 26
    Reported Aug 7
    		$-0.12$-0.08-50.00%Miss-5554.5%
    Mar 26
    Reported May 7
    		$-0.10$-0.07-42.86%Miss-2425.6%
    Dec 25
    Reported Mar 12
    		$0.05$0.05+0.21%Beat+4354.5%
    Sep 25
    Reported Nov 7
    		$0.03$-0.02+250.00%Beat+129.0%
    Jun 25
    Reported Aug 11
    		$0.00N/A-92.67%Miss-93.5%
    Mar 25
    Reported May 9
    		$0.00N/A-85.67%Miss-86.4%
    Dec 24
    Reported Mar 17
    		$-0.00N/A-102.75%Miss-
    Sep 24
    Reported Nov 13
    		$0.01N/AN/ABeat+101.2%
    Jun 24
    Reported Aug 13
    		$0.03N/AN/ABeat+103.2%
    Mar 24
    Reported May 9
    		$0.03$0.00N/ABeat-78.9%
    Dec 23
    Reported Mar 26
    		$0.00N/A+100.00%Beat+100.0%
    Sep 23
    Reported Oct 26
    		$-1.05$-0.75-40.00%Miss+56.3%
    Jun 23
    Reported Aug 14
    		$-1.05$-0.07-1400.00%Miss-104.3%
    Mar 23
    Reported May 15
    		$0.15$-0.07+314.29%Beat+102.2%
    Dec 22
    Reported Mar 30
    		$-19.05$-0.10-18042.86%Miss-95.4%
    Sep 22
    Reported Nov 14
    		$-2.40$-0.10-2300.00%Miss+80.0%
    Jun 22
    Reported Aug 15
    		$24.60$-0.24+10140.82%Beat+356.3%
    Mar 22
    Reported May 9
    		$-6.90$-0.46-1410.84%Miss+41.8%
    Dec 21
    Reported Mar 31
    		$-9.75$-0.59-1559.57%Miss+24.4%
    Sep 21
    Reported Nov 12
    		$-12.00$-0.66-1718.18%Miss-9.6%
    Jun 21
    Reported Aug 5
    		$-9.60$-0.69-1281.30%Miss+33.3%
    Mar 21
    Reported May 6
    		$-11.85$-0.58-1951.95%Miss-182.1%
    Dec 20
    Reported Mar 4
    		$-12.90$-0.86-1395.65%Miss+30.1%
    Sep 20
    Reported Nov 5
    		$-10.95$-0.81-1257.38%Miss+31.1%
    Jun 20
    Reported Aug 6
    		$-14.40$-0.86-1574.42%Miss+16.5%
    Mar 20
    Reported May 11
    		$-4.20$-0.37-1035.14%Miss+77.8%
    Dec 19
    Reported Feb 20
    		$-18.45$0.17-10952.94%Miss-35.2%
    Sep 19
    Reported Nov 7
    		$-15.90$-1.16-1270.69%Miss-65.6%
    Jun 19
    Reported Aug 1
    		$-17.25$-1.11-1454.05%Miss-113.0%
    Mar 19
    Reported May 2
    		$-18.90$-1.08-1650.00%Miss-125.0%
    Dec 18
    Reported Mar 8
    		$-13.65$-0.75-1720.00%Miss-992.0%
    Sep 18
    Reported Nov 1
    		$-9.60$-0.59-1527.12%Miss+52.2%
    Jun 18
    Reported Aug 2
    		$-8.10$-0.62-1206.45%Miss-432.9%
    Mar 18
    Reported May 3
    		$-8.40$-0.92-813.04%Miss-83.8%
    Dec 17
    Reported Mar 19
    		$-1.25$-1.53+18.30%Beat+73.1%
    Sep 17
    Reported Nov 2
    		$-20.10$-1.32-1422.73%Miss-
    Jun 17
    Reported Aug 3
    		$-1.52$-1.46-4.11%Miss-
    Mar 17
    Reported May 11
    		$-4.57$-6.10+25.08%Beat-
    Dec 16
    Reported Mar 8
    		$-4.65$-5.63+17.41%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%

    Key Metrics

    Valuation
    P/E Ratio-31.81EV/EBITDAN/A
    Price/FCF-29.11xFCF Yield-3.44%
    Profitability
    Profit Margin-19.30%Operating Margin-47.60%
    ROE-17.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-7.26x
    Current Ratio4.26xQuick Ratio3.86x
    Trading Statistics
    Beta4.74Avg Volume140.69K
    52-Week High$9.1452-Week Low$4.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.05
    SMA 20$6.42
    SMA 50$6.73
    SMA 200$6.99
    EMA 10$6.07
    EMA 20$6.32
    EMA 50$6.57
    EMA 200$6.94

    MACD

    Line: -0.29Signal: -0.20Hist: -0.08

    ADX

    ADX: 24.1+DI: 19.5-DI: 40.9

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$7.10

    Bollinger Bands

    Upper Band$7.69
    Lower Band$5.14
    %B Position3976%(Upper)
    Band Width-0.23

    RSI (14-Day)

    Oversold
    29.5

    Momentum Oscillators

    Stoch %K50.5
    Stoch %D60.7
    Williams %R-98.5
    ROC (10d)-25.1%
    Momentum-1.52
    CCI (20d)-199.6
    MFI (14d)28.6

    Volatility Measures

    ATR (14d)$0.48(10.6%)
    StdDev (20d)0.64
    Hist Vol122.6%(High)

    Volume Flow

    VWAP$5.12
    OBV-1.4M
    AD Line-6.3M
    CMF (20d)-0.349

    Volume Metrics

    Avg Vol (20d)139.6K
    Vol Ratio2.8x(High)
    VWMA (20d)$6.22

    Pivot Points

    R3$7.42
    R2$7.20
    R1$6.81
    Pivot Point$6.59
    S1$6.19
    S2$5.97
    S3$5.58

    Advanced Oscillators

    TSI-19.89
    Ultimate Osc37.6
    KST-125.66

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$29.11M$22.52M$37.20M$30.56M$29.73M$22.06M$27.87M$25.49M$25.23M$27.17M$27.15M$32.04M
    Cost of Revenue$2.21M$1.23M$1.74M$1.63M$1.15M$894,000$1.18M$958,000$770,000$979,000$1.25M$1.18M
    Gross Profit$26.90M$21.29M$35.45M$28.94M$28.58M$21.16M$26.70M$24.53M$24.45M$26.19M$25.90M$30.86M
    Operating Expenses$41.26M$30.65M$35.33M$22.01M$30.82M$18.89M$26.03M$20.30M$21.26M$18.12M$117.00M$18.62M
    R&D$19.14M$6.74M$4.82M$2.36M$8.35M$3.10M$3.71M$2.77M$3.35M$2.18M$87.67M$3.01M
    SG&A$7.87M$7.22M$6.70M$4.32M$7.28M$4.96M$5.46M$3.82M$3.42M$3.40M$10.05M$1.16M
    Operating Income$-14,363,000$-9,355,000$118,000$6.92M$-2,240,000$2.27M$665,000$4.23M$3.19M$8.07M$-91,632,000$12.76M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-740,000$0$184,000$0$-941,000$0$0$303,000$0$0$-326,000$-283,000
    Income Before Tax$-14,434,000$-9,237,000$-66,000$7.63M$-1,575,000$4.63M$772,000$3.93M$6.04M$12.48M$-100,278,000$11.19M
    Income Tax Expense$-164,000$621,000$1.30M$1.69M$662,000$901,000$203,000$1.07M$1.50M$2.55M$699,000$3.68M
    Net Income$-14,270,000$-9,858,000$-1,366,000$5.94M$-2,237,000$3.73M$569,000$2.86M$4.54M$9.94M$-100,977,000$7.51M
    EBITDA$-13,691,000$-8,565,000$-1,157,000$8.28M$-1,507,000$5.17M$-314,000$4.38M$6.26M$12.90M$-100,822,000$11.63M
    EBIT$-15,174,000$-9,237,000$-1,813,000$7.63M$-2,516,000$4.63M$-775,000$3.93M$6.04M$12.48M$-101,130,000$11.43M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GYRE

    News

    Gyre Therapeutics, Inc. Estimates – NASDAQ:GYRE

    This article provides an overview of Gyre Therapeutics, Inc. (NASDAQ:GYRE) financial data and analyst estimates available on TradingView. It highlights where to explore reported financial data across income statements...

    TradingView•10/23/26•Neutral

    Gyre Therapeutics signs new employment agreements with CEO Ying Luo and CFO Thomas Eastling

    Gyre Therapeutics has entered into new employment agreements with its CEO, Ying Luo, and CFO, Thomas Eastling, both of whom will continue in their respective roles. The agreements became effective on October 16, 2026...

    TradingView•10/22/26•Somewhat-Bullish

    H.C. Wainwright reiterates USD 18.00 target for Gyre Therapeutics stock

    H.C. Wainwright has reiterated a Buy rating and a USD 18.00 price target for Gyre Therapeutics (GYRE). This comes after Gyre's second-quarter 2026 revenue of USD 29.11 million exceeded expectations...

    ad-hoc-news.de•10/20/26•Somewhat-Bullish

    Gyre Therapeutics stock falls 5.00 percent to USD 6.08 on October 16, 2026

    Gyre Therapeutics (GYRE) stock fell 5.00 percent to USD 6.08 on October 16, 2026, closing its Nasdaq session. The biotechnology company reported Q2 2026 revenue of USD 29.11 million, exceeding analyst estimates...

    ad-hoc-news.de•10/17/26•Bearish

    H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock

    H.C. Wainwright has reiterated its Buy rating and USD 18.00 price target for Gyre Therapeutics, despite the company reporting a wider-than-expected loss in Q2 2026...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    GYRE Valuation and Fair Value

    P/E
    -31.8x
    Forward P/E
    188.7x
    P/FCF
    -29.1x
    P/B
    4.2x
    See GNG's fair value

    GYRE Profitability: Margins, ROIC and FCF

    Gross margin
    94.3%
    Operating margin
    -47.6%
    Net margin
    -19.3%
    ROE
    -17.4%
    FCF margin
    -13.2%
    FCF yield
    -3.4%

    GYRE Competitors

    CompanyTicker
    Avita Medical LtdRCEL
    Evolent Health IncEVH
    Evolus IncEOLS
    XOMA CorpXOMA
    Delcath Systems IncDCTH
    Regenxbio IncRGNX
    DiaMedica Therapeutics IncDMAC
    Phathom Pharmaceuticals IncPHAT

    Sector: Healthcare

    GYRE Bull Case vs Bear Case

    Bear case

    • GYRE has a -19.3% net profit margin.
    • GYRE beat EPS estimates in 37.5% of its last 8 reported quarters.
    • GYRE's quarterly revenue changed -2.1% year over year.

    GYRE Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -17.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.12
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    GYRE Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About GYRE

    Does GYRE pay dividends?

    Gyre Therapeutics Inc. (GYRE) has a dividend payment track record. See the GYRE dividend history page for its current payment status, TTM yield, and recorded payments.

    What is GYRE's market cap?

    Gyre Therapeutics Inc. (GYRE) has a market capitalization of $482.98M with a current stock price of $4.55.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In